Terms ending in 2041
Every in-force patent on Forma Therapeutics, Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,053,458 | Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound In force · High confidence | Novo Nordisk Health Care AG | In force | High confidence | |
| US 11,566,013 | Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH1) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,795,168 | Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 12,454,532 | Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP) In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 12,252,490 | Inhibiting Deubiquitinase USP25 and USP28 In force · High confidence | Valo Health, Inc. | In force | High confidence | |
| US 12,049,466 | Fused Bicyclic Compounds Useful as Ubiquitin-Specific Peptidase 30 Inhibitors In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 11,801,243 | Bromodomain Inhibitors for Androgen Receptor-Driven Cancers In force · High confidence | Forma Therapeutics, Inc. | In force | High confidence | |
| US 12,122,778 | Activating Pyruvate Kinase R In force · Medium confidence | Novo Nordisk Health Care AG | In force | Medium confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by Forma Therapeutics, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.